Cargando…

The CH1α domain of mucosal gp41 IgA contributes to antibody specificity and antiviral functions in HIV-1 highly exposed Sero-Negative individuals

The antibody molecule comprises a variable domain conferring antigen specificity and affinity distinct from the heavy chain constant (CH) domains dictating effector functions. We here interrogate this paradigm by evaluating the unique influence of the CH1α domain on epitope specificity and functions...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khamassi, Marwa, Xu, Lin, Rey, Julien, Duchemin, Maxence, Bouceba, Tahar, Tuffery, Pierre, Tudor, Daniela, Bomsel, Morgane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802955/ https://www.ncbi.nlm.nih.gov/pubmed/33315937 http://dx.doi.org/10.1371/journal.ppat.1009103

Ejemplares similares

IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis
por: Duchemin, Maxence, et al.
Publicado: (2018)

Antibody-Dependent Cellular Phagocytosis of HIV-1-Infected Cells Is Efficiently Triggered by IgA Targeting HIV-1 Envelope Subunit gp41
por: Duchemin, Maxence, et al.
Publicado: (2020)

The Protective HIV-1 Envelope gp41 Antigen P1 Acts as a Mucosal Adjuvant Stimulating the Innate Immunity
por: Xu, Lin, et al.
Publicado: (2021)

P11-20. HIV-1 gp41-specific mucosal IgAs from highly exposed but IgG seronegative women block HIV-1 epithelial transcytosis and neutralize CD4+ cell infection
por: Tudor, D, et al.
Publicado: (2009)

Peptide P5 (residues 628–683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection
por: Yu, Huifeng, et al.
Publicado: (2008)

Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes
por: Leroux-Roels, Geert, et al.
Publicado: (2013)

Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA
por: Cottignies-Calamarte, Andréa, et al.
Publicado: (2023)

Reverse Immunology Approach to Define a New HIV-gp41-Neutralizing Epitope
por: Dorgham, Karim, et al.
Publicado: (2019)

P19-02. High protection of female macaques from repeated intravaginal challenges with SHIV-162P3 upon mucosal vaccination with Gp41 subunits-virosomes
por: Bomsel, M, et al.
Publicado: (2009)

The immunoglobulin CH1 constant region modulates antigen binding affinity and functional activities of the broadly neutralizing 2F5 HIV specific antibody
por: Tudor, Daniela, et al.
Publicado: (2010)

Editorial: Mucosal immunity to HIV and SARS-CoV-2 infection and vaccination
por: Bomsel, Morgane, et al.
Publicado: (2023)

Neutralizing Antibodies Targeting HIV-1 gp41
por: Caillat, Christophe, et al.
Publicado: (2020)

HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life
por: Yates, N L, et al.
Publicado: (2013)

Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy
por: Nabi, Rafiq, et al.
Publicado: (2017)

Convergent HIV-1 Evolution upon Targeted Destabilization of the gp120-gp41 Interface
por: Torrents de la Peña, Alba, et al.
Publicado: (2021)

gp41: HIV's shy protein
por: Zwick, Michael B, et al.
Publicado: (2004)

Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41
por: Sanders, Rogier W, et al.
Publicado: (2004)

Membrane topology analysis of HIV-1 envelope glycoprotein gp41
por: Liu, Shujun, et al.
Publicado: (2010)

Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis
por: Ruiz, Maria Julia, et al.
Publicado: (2022)

New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes
por: Amacker, Mario, et al.
Publicado: (2020)

3D6 and 4B3: Recombinant expression of two anti-gp41 antibodies as dimeric and secretory IgA
por: Reinhart, David, et al.
Publicado: (2011)

Enhancing Exposure of HIV-1 Neutralization Epitopes through Mutations in gp41
por: Blish, Catherine A, et al.
Publicado: (2008)

Asymmetric Deactivation of HIV-1 gp41 following Fusion Inhibitor Binding
por: Kahle, Kristen M., et al.
Publicado: (2009)

Approaches for Identification of HIV-1 Entry Inhibitors Targeting gp41 Pocket
por: Yu, Fei, et al.
Publicado: (2013)

Human and chicken antibodies to CCR5-ECL1 block mucosal and systemic HIV infection
por: Lopalco, Lucia, et al.
Publicado: (2006)

Rational Design of A Novel Small-Molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1
por: Pu, Jing, et al.
Publicado: (2021)

Allosteric Modulation of the HIV-1 gp120-gp41 Association Site by Adjacent gp120 Variable Region 1 (V1) N-Glycans Linked to Neutralization Sensitivity
por: Drummer, Heidi E., et al.
Publicado: (2013)

HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions
por: Qi, Qianqian, et al.
Publicado: (2017)

P02-10. Plant expression of chimeric Gag/gp41 virus-like particles as a mucosally-targeted subunit vaccine against HIV-1
por: Kessans, SA, et al.
Publicado: (2009)

Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope
por: Penn-Nicholson, Adam, et al.
Publicado: (2008)

TRPV1 activation in human Langerhans cells and T cells inhibits mucosal HIV-1 infection via CGRP-dependent and independent mechanisms
por: Mariotton, Jammy, et al.
Publicado: (2023)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Analysis of gp41 epitopes in model viral membranes to study HIV-1 neutralization
por: Reichart, T, et al.
Publicado: (2012)

Modulation of Cytokine Release and Gene Expression by the Immunosuppressive Domain of gp41 of HIV-1
por: Denner, Joachim, et al.
Publicado: (2013)

HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development
por: Verkoczy, Laurent, et al.
Publicado: (2014)

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
por: Huang, Jinghe, et al.
Publicado: (2012)

Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer
por: Khasnis, Mukta D., et al.
Publicado: (2016)

Structure of HIV-1 gp41 with its membrane anchors targeted by neutralizing antibodies
por: Caillat, Christophe, et al.
Publicado: (2021)

A Functional Role for the Monomethylated Gln-51 and Lys-53 Residues of the 49GGQTK53 Motif of eL42 from Human 80S Ribosomes
por: Eustache, Stéphanie, et al.
Publicado: (2017)

Striking HIV-1 Entry by Targeting HIV-1 gp41. But, Where Should We Target?
por: Teixeira, Cátia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6r0ptb5b681af3bh4qo3pg1ubb